Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.

B Escudier, J Bellmunt, S Negrier, P Kellokumpu-Lehtinen

Research output: Contribution to journalArticleScientificpeer-review

658 Citations (Scopus)
Original languageEnglish
Pages (from-to)2144-2150
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume28
Issue number13
Publication statusPublished - 2010
Publication typeA1 Journal article-refereed

Cite this